The truth about Tamiflu?

Neuraminidase inhibitors in pandemic A/H1N1 flu

BMJ 2010; 340 doi: http://dx.doi.org/10.1136/bmj.c130 (Published 13 January 2010)
Cite this as: BMJ 2010;340:c130

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. J Todd Weber, on assignment from US Centers for Disease Control and Prevention1,
  2. Angus Nicoll, coordinator1,
  3. Carolyn B Bridges, associate director for science2,
  4. Bruno C Ciancio, senior expert1
  1. 1Influenza Programme, European Centre for Disease Prevention and Control (ECDC), 171 83 Stockholm, Sweden
  2. 2Influenza Division, Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA
  1. jtodd.weber{at}ecdc.europa.eu

    Jefferson and colleagues describe the effectiveness of neuraminidase inhibitors in otherwise healthy adults infected with seasonal flu virus,1 but it is mainly the A/H1N1 flu virus that is currently in circulation.

    Given the limited availability of vaccine against 2009 pandemic A/H1N1 flu, antiviral drugs have assumed a prominent role in reducing severe flu …

    Get access to this article and all of bmj.com for the next 14 days

    Sign up for a 14 day free trial today

    Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    THIS WEEK'S POLL